CYP2C9 gene analysis of some Iranian hypersensitive patients to warfarin.
For the first time in this study, the pharmacogenetic effects of CYP2C9 polymorphism on warfarin sensitivity in some Iranian patients who are on warfarin treatment were shown. The study group consisted of clinically sensitive patients (21 patients) and the control group (37 adult patients). For detection of CYP2C9*2 and CYP2C9*3 variants, a protocol based on restriction fragment length polymorphism based polymerase chain reaction with Eco47I and KpnI was used. In clinically sensitive patients about 81% and in normal response patients about 24.3% carried variant genotypes.
Ghadam
P
P
Department of Biology, Faculty of Basic Sciences, Alzahra University, Tehran, Iran.
Sharifian
R
R
Farsangi
Z Jomeh
ZJ
Kianmehr
Z
Z
Lak
M
M
D000925:Anticoagulants / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D016022:Case-Control Studies; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D007492:Iran; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D011110:Polymorphism, Genetic; D014859:Warfarin / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use
D000925:Anticoagulants; D007527:Isoenzymes; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases